Esketamine is the S-enantiomer of ketamine and is FDA-approved for treatment-resistant depression when administered intranasally under medical supervision. It is approximately 4 times more potent at NMDA receptors than the R-enantiomer and approximately 2 times more potent than racemic ketamine. Side effects include dissociation, dizziness, sedation, increased blood pressure, and nausea. Contraindicated in individuals with aneurysmal vascular disease, uncontrolled hypertension, or history of psychosis. Available only through REMS program (Spravato REMS) in the US.
Esketamīns molecular structure diagram from the DrugsPRO substance library.
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Esketamine - DrugsPRO vielu ceļvedis
Esketamine: Esketamine is the S-enantiomer of ketamine and is FDA-approved for treatment-resistant depression when administered intranasally under medical supervision. It is approximately 4 times more potent at NMDA receptors than the R-enantiomer and approximately 2 times more potent than racemic k
